Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

Figure 2 Frequencies of genetic alternations and expression of FABP4 and FABP5 in various cancer types. A-B: Frequencies of genetic alternations of FABP4 in major cancer types using The Cancer Genome Atlas (TCGA) datasets via cBioportal (A) and in various liver cancer subtypes (B) using TCGA datasets via cBioportal; C-D: Frequencies of genetic alternations of FABP5 in pan-cancer types (C) and in various liver cancer subtypes (D) using TCGA datasets via cBioportal; E: FABP5 expression in liver cancer with different FABP5 genetic alteration types using TCGA datasets via cBioportal; F: Expression of FABP5 (left panel) and FABP4 (right panel) in liver cancer at stage I-IV using TCGA datasets via GEPIA2 portal. ^dP < 0.0001; NS: Not significant.